Avelumab and Merkel Cell Carcinoma: Legal Considerations and Statute of Limitations in North Carolina

From General Health Surveillance to Targeted Occupational Exposure

For decades, mass production environments have been a cornerstone of public health surveillance, with general health and science information serving as the foundation for identifying workplace hazards. This legacy framework has historically focused on broad exposure categories, such as chemical irritants or physical stressors, without delving into specific pharmaceutical agents or their downstream effects. However, as industrial processes evolve, the need to refine this lens becomes apparent—particularly when production lines involve biologic or immunomodulatory compounds. In the context of modern manufacturing, the transition from general health monitoring to targeted occupational exposure concern is driven by the increasing use of therapeutic proteins in mass production settings. One such compound, Avelumab, a monoclonal antibody employed in oncology, presents a distinct case for workplace scrutiny. While its therapeutic application is well-documented, the potential for occupational exposure during formulation, filling, or packaging raises questions about long-term health implications for workers. This pivot is not about asserting causal mechanisms but about acknowledging that routine industrial handling of such agents may warrant specific attention under existing regulatory frameworks. Thus, the shift from a broad health-and-science heritage to a focused exposure concern is a logical progression—one that aligns with the principle of precaution in occupational medicine. The query regarding Avelumab and Merkel cell carcinoma, particularly in the context of North Carolina’s statute of limitations, exemplifies how legacy surveillance must adapt to address novel industrial realities without overstepping into mechanistic speculation.

Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval for avelumab in metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The FDA-approved labeling for avelumab indicates its use for adults and pediatric patients 12 years and older with metastatic MCC (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118). Merkel cell carcinoma is a very rare but highly aggressive cutaneous neuroendocrine carcinoma associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence rate of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in this setting (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Risk Context: Non-Response and Disease Progression

Regarding the adequacy of warnings, the FDA-approved labeling for avelumab includes indications for metastatic MCC, but the label does not explicitly warn that avelumab may cause or worsen MCC. Rather, avelumab is indicated as a treatment for MCC. The mechanistic pathway linking avelumab to MCC is not one of causation but of therapeutic intervention: avelumab blocks PD-L1, thereby enhancing the immune system's ability to attack tumor cells. However, the risk narrative for patients in North Carolina considering a settlement related to avelumab and MCC must consider the timeline between exposure and documented harm. Since avelumab is used to treat existing MCC, the "exposure" is the administration of the drug to a patient already diagnosed with MCC. The "harm" in this context would be progression of MCC despite avelumab treatment, or adverse effects from the drug itself. The JAVELIN Merkel 200 trial demonstrated that approximately one-third of patients responded, meaning two-thirds did not have an objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). Additionally, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Thus, a significant proportion of patients may experience disease progression while on avelumab. Settlement-related considerations for affected patients in North Carolina must account for the statute of limitations for product liability claims. In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For avelumab-treated MCC patients, the "injury" could be progression of MCC or development of adverse effects. The timeline between exposure (initiation of avelumab) and documented harm (disease progression or adverse event) is variable. In the JAVELIN Merkel 200 trial, responses were assessed over time, but progression could occur at any point during treatment. Patients who experienced progression while on avelumab would have a documented harm at the time of progression. The statute of limitations clock would start from that date or from when the patient knew or should have known that the progression was related to avelumab treatment. Given that avelumab is approved for MCC and is not known to cause MCC, the legal theory for a settlement would likely not be based on avelumab causing MCC, but rather on failure to adequately warn about the risk of non-response or progression. The adequacy of warnings regarding avelumab and MCC is a key risk anchor. The FDA-approved label includes efficacy data from clinical trials, but it does not explicitly warn that a significant proportion of patients may not respond or may progress. However, the label does state that avelumab is indicated for treatment, implying that it is not a guaranteed cure. Patients and their attorneys would need to evaluate whether the warnings provided were sufficient to allow informed decision-making. In summary, for patients in North Carolina considering a settlement related to avelumab and MCC, the evidence indicates that avelumab is a treatment for MCC, not a cause. The harm experienced by patients is typically disease progression or adverse effects. The statute of limitations in North Carolina is three years from discovery of harm. Settlement considerations should focus on the adequacy of warnings regarding the likelihood of non-response and progression, as well as the timeline between treatment initiation and documented harm. References: https://pubmed.ncbi.nlm.nih.gov/33439294/ https://pubmed.ncbi.nlm.nih.gov/29799096/ https://pubmed.ncbi.nlm.nih.gov/36450381/ https://pubmed.ncbi.nlm.nih.gov/35877101/ https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for avelumab-related claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For avelumab-treated Merkel cell carcinoma patients, the injury could be disease progression or adverse effects, and the clock starts from the date of documented harm or discovery of its link to avelumab.

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor that blocks PD-L1 to enhance the immune system's attack on tumor cells. The drug is approved for metastatic MCC, and the harm experienced by patients is typically disease progression or adverse effects, not causation of MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.